Vascular Endothelial Growth Factor Levels in Childhood Acute Lymphoblastic and Myeloblastic Leukemia

Leblebisatan, Göksel; Antmen, Bülent; Şaşmaz, İlgen; Kılınç, Yurdanur

doi:10.1007/s12288-011-0102-2

Cited by 8 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most predominant isoform is VEGF165 which exhibits optimal bioavailability, it is responsible for the biological potency of VEGF, and it is specifically bound by NRP-1 (Whitaker et al, 2001). Leblebisatan et al (2012) reported that mRNA levels of VEGF were higher in acute myelogenous leukemia patients compared with their control group, while there was no significant difference between acute lymphoblastic leukemia patients and the control group. However, the data from showed the VEGF mRNA expression was significantly higher in acute lymphoblastic leukemia patients compared with their control group.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

The Neuropilin‐1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia

Yang

Wen

et al. 2018

The Anatomical Record

View full text Add to dashboard Cite

Semaphorin‐3A (Sema3A) and vascular endothelial growth factor (VEGF165) are ligands of neuropilin‐1 (NRP‐1 or CD304) and are related to immunoregulation and tumor angiogenesis, respectively. However, possible interactions between NRP‐1 and Sema3A and VEGF165 in acute leukemia remain unclear, especially whether Sema3A plays a role in acute leukemia. In this study, both of the proportion of regulatory T cells (Tregs) and their expression of NRP‐1 were found to increase in acute leukemia patients compared with healthy controls. In contrast, lower mRNA and plasma levels of Sema3A were detected in the acute leukemia patients. In vitro, the addition of exogenous Sema3A inhibited the expression of NRP‐1 on Tregs and it promoted apoptosis of leukemia cells. However, in the presence of anti‐Sema3A antibody, the effect of rhSema3A on NRP‐1 expression was reversed. These results suggest that Sema3A promotes apoptosis in leukemia cells by inhibiting expression of NRP‐1, and thus, represents a tumor suppressor protein with a role in the pathogenesis of acute leukemia. Consequently, NRP‐1/Sema3A signaling may represent a novel target for the treatment of acute leukemia and should be further studied. Anat Rec, 302:1127–1135, 2019. © 2018 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 95%

“…Leblebisatan et al . () reported that mRNA levels of VEGF were higher in acute myelogenous leukemia patients compared with their control group, while there was no significant difference between acute lymphoblastic leukemia patients and the control group. However, the data from Yang et al .…”

Section: Discussionmentioning

confidence: 97%

The Neuropilin‐1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia

Yang

Wen

et al. 2018

The Anatomical Record

View full text Add to dashboard Cite

show abstract

“…[4][5][6] ). Alterations in this interacting functional network may have direct effect on the malignant cells or have indirect effect on leukemogenesis through altered functions of bone marrow stromal elements [7][8][9] .…”

Section: Introductionmentioning

confidence: 99%

Serum cytokine and adhesion molecule profile differs in newly diagnosed acute myeloid and lymphoblastic leukemia

Horáček¹,

Kupsa²,

Vašatová³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

Aims.To compare serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) using biochip array technology. Methods. A total of 15 AML and 15 ALL patients were studied. Serum samples were taken prior to anticancer therapy and were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. This approach allows simultaneous detection of multiple analytes from a single sample. T-tests were used for statistical analysis. Results. Comparing cytokine and adhesion molecules levels in newly diagnosed AML and ALL patients, we found significant increase in AML in serum IL-4 (P < 0.0001), IL-2 (P < 0.01), IL-3 (P < 0.05), and significant decrease (P < 0.05) in serum VEGF and VCAM-1. Discussion. Our results indicate that serum profile of cytokines and adhesion molecules differs in newly diagnosed AML and ALL patients. Further studies are needed to establish if these alterations could be used as a clinically relevant biomarker for acute leukemias.

show abstract

“…13 Median VEGF level in standard risk protocol patients was significantly decreased after chemotherapy compared to before chemotherapy. Leblebisatan et al 14 found that VEGF was higher in leukemia subjects than in healthy subjects. In addition, VEGF levels were not significantly different between AML and ALL patients, but VEGF levels at remission were lower than at the time of initial diagnosis.…”

Section: Discussionmentioning

confidence: 97%

Vascular endothelial growth factor (VEGF) expression in induction phase chemotherapy of acute lymphoblastic leukemia

Daud

Astari

Ridha

2019

View full text Add to dashboard Cite

Background Leukemia is a hematolymphoid malignancy originating from bone marrow. The progression of hematolymphoid malignancies depends on new formation of vasculature, called angiogenesis. Angiogenesis is regulated by vascular endothelial growth factor (VEGF), which is secreted by paracrine and autocrine signaling mechanisms. Objective To evaluate VEGF expression in induction phase chemotherapy of acute lymphoblastic leukemia (ALL) patients. Methods This prospective, cohort study was conducted in ALL patients admitted to Dr. Wahidin Sudirohusodo Hospital, Makassar, South Sulawesi, from October 2016 to October 2017. Subjects’ VEGF levels were measured at diagnosis and at the end of induction chemotherapy. Results VEGF levels were analyzed in 59 patients, 29 of whom were diagnosed with standard risk ALL and 30 patients with high risk ALL. VEGF levels were significantly decreased after induction phase chemotherapy in standard risk ALL and in high risk ALL subjects. There was no significant difference in VEGF levels before induction phase chemotherapy between the standard and high risk groups (P=0.405). There was also no significant difference in VEGF levels after induction phase chemotherapy between the two risk groups (P=0.094). Conclusion The VEGF level is significantly lower after ALL induction phase chemotherapy in both the standard risk and high risk ALL groups. However, there are no significant differences in VEGF levels between the standard and high risk groups before as well as after induction phase chemotherapy.

show abstract

Vascular Endothelial Growth Factor Levels in Childhood Acute Lymphoblastic and Myeloblastic Leukemia

Cited by 8 publications

References 27 publications

The Neuropilin‐1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia

The Neuropilin‐1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia

Serum cytokine and adhesion molecule profile differs in newly diagnosed acute myeloid and lymphoblastic leukemia

Vascular endothelial growth factor (VEGF) expression in induction phase chemotherapy of acute lymphoblastic leukemia

Contact Info

Product

Resources

About